The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cancer Research Communications
Open accessAbstract
A 23-year-old male patient, who suffers from beta-thalassemia major, came to us for an endocrine-metabolic evaluation. Medical history showed a diagnosis of heart disease with heart failure since the age of 16, type 1 diabetes mellitus diagnosed at the age of 18, treated with an intensive insulin therapy with a poor glycometabolic control. Patient performed regular blood transfusions and iron chelation with deferasirox. An echocardiogram revealed an enlarged left ventricle. Patient had undergone a comprehensive study of buoyancy both basal and hormone-stimulated and it was therefore carried out a diagnosis of GH deficiency and hypogonadotropic hypogonadism. A recombinant GH replacement therapy was then prescribed. After six months of therapy, the patient reported a net improvement of asthenic symptoms. Physical examination showed a reduction in abdominal adiposity in waist and an increase of 5 cm in stature. Laboratory tests showed an amelioration of glycometabolic control, such as to justify a reduction in daily insulin dose. The stature observed was thought appropriate to begin the administration of testosterone. Moreover, the cardiological framework showed a reduction of left ventricular dilatation, good ventricular motility, global minimum persistent tricuspid but not mitral regurgitation and no alteration on ECG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Dolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Epidemiology and molecular pathology of glioma
Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., & Wrensch, M. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0289 · Cited by 949
Lutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Phenotypical and functional specialization of FOXP3+ regulatory T cells
Campbell, D. J., & Koch, M. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri2916 · Cited by 773
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou307 · Cited by 585
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
KOMOTAR, R. J., WILSON, D. A., & CONNOLLY, E. S. (2005) · Neurosurgery · doi:10.1093/neurosurgery/57.1.n7a · Cited by 570
Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 564
Schuster, J., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugala, M. M., Jensen, R., Baehring, J. M., Sloan, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou348 · Cited by 422
Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 370
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300
c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype
Li, Y., Li, A., Glas, M., Lal, B., Ying, M., Sang, Y., Xia, S., Trageser, D., Guerrero-Cázares, H., Eberhart, C. G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016912108 · Cited by 266
Vaccine adjuvant uses of poly-IC and derivatives
Martins, K. A., Bavari, S., & Salazar, A. M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.966085 · Cited by 220
Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
Kaufman, H. L., Ruby, C. E., Hughes, T., & Slingluff, C. L. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-11 · Cited by 212
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
Dutoit, V., Herold-Mende, C., Hilf, N., Schoor, O., Beckhove, P., Bucher, J., Dorsch, K., Flohr, S., Fritsche, J., Lewandrowski, P., et al. (2012) · Brain · doi:10.1093/brain/aws042 · Cited by 201
Low dose cyclophosphamide: Mechanisms of T cell modulation
Madondo, M. T., Quinn, M., & Plebanski, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.005 · Cited by 188
Ahlers, J., Dunlop, N. M., Alling, D. W., Nara, P. L., & Berzofsky, J. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3947 · Cited by 154
Butt, A., & Mills, K. H. G. (2013) · Oncogene · doi:10.1038/onc.2013.432 · Cited by 151
WINNEY, B. J., Boumertit, A., Day, T., Davison, D., Echeta, C., Evseeva, I., Hutnik, K., Leslie, S., Nicodemus, K. K., Røyrvik, E. C., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.127 · Cited by 150
Fadul, C. E., Fisher, J. L., Gui, J., Hampton, T. H., Côté, A. L., & Ernstoff, M. S. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq204 · Cited by 146
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
Wainwright, D. A., Dey, M., Chang, A. L., & Lesniak, M. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00116 · Cited by 144
Khurana, V. G., Jain, S., Smee, R., Cook, R., Dobes, M., Shadbolt, B., Smith, S., & Dexter, M. A. J. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.90696 · Cited by 134
Fu, J. L., Malm, I., Kadayakkara, D. K. K., Levitsky, H., Pardoll, D. M., & Kim, Y. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2685 · Cited by 133
GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men
Hege, K. M., Jooss, K. U., & Pardoll, D. M. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992498 · Cited by 113
Evolution of end points for cancer immunotherapy trials
Hoos, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds263 · Cited by 103
for the HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group, Britten, C. M., Janetzki, S., Ben‐Porat, L., Clay, T. M., Kalos, M. D., Maecker, H. T., Odunsi, K. O., Pride, M. W., Old, L. J., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0681-z · Cited by 67
Enhanced immunosuppression by therapy‐exposed glioblastoma multiforme tumor cells
Authier, A., Farrand, K. J., Broadley, K. W. R., Ancelet, L. R., Hunn, M. K., Stone, S., McConnell, M. J., & Hermans, I. F. (2014) · International Journal of Cancer · doi:10.1002/ijc.29309 · Cited by 49
Chudley, L., McCann, K. J., Coleman, A., Cazaly, A. M., Bidmon, N., Britten, C. M., van der Burg, S. H., Gouttefangeas, C., Jandus, C., Laske, K., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1593-0 · Cited by 39
Immunotherapy of Genitourinary Malignancies
Inamoto, T., & Azuma, H. (2012) · Journal of Oncology · doi:10.1155/2012/397267 · Cited by 11
Cited by
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Application of Radiosensitizers in Cancer Radiotherapy
Gong, L., Zhang, Y., Liu, C., Zhang, M., & Han, S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s290438 · Cited by 479
Lu, C., Rong, D., Zhang, B., Zheng, W., Wang, X., Chen, Z., & Tang, W. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1047-6 · Cited by 418
Metadata
- Published
- 2021-08-27
- OpenAlex
- W4210738594
- Cited by
- 1,532
- References
- 35
- Type
- paratext
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.